# Brain & Body Reset: A 360° Playbook to Dislodge Adult ADHD and Trauma—From FDA Gold-Standards to 4,000-Year-Old Rituals

## Executive Summary

Managing the complex interplay of adult ADHD and trauma requires a multifaceted, personalized strategy, as no single intervention addresses the full spectrum of neurobiological and somatic symptoms. The therapeutic landscape spans high-efficacy modern medicine, emerging brain-stimulation technologies, and ancient mind-body practices, each with distinct risk-reward profiles. The most effective path forward involves layering these interventions, starting with foundational lifestyle changes and gold-standard psychotherapies, and personalizing the approach with measurement-based care.

**Dual Gold Standards Offer Durable Change but Face Access Hurdles.** For the trauma component, trauma-focused psychotherapies like EMDR, CPT, and PE are the undisputed first-line treatments, demonstrating large, durable benefits with high remission rates. [executive_summary[19]][1] [executive_summary[27]][2] [executive_summary[33]][3] For ADHD, Cognitive Behavioral Therapy (CBT) stands out as the most effective non-pharmacological intervention, showing significant long-term reduction in core symptoms and related emotional distress. [executive_summary[3]][4] [executive_summary[4]][5] The primary barrier to these transformative therapies is practical: high costs ($100-$250 per session) and long provider waitlists (often exceeding 1.5 years in public systems) limit accessibility. [cost_access_and_policy_considerations.provider_availability_and_waitlists[1]][6]

**Pharmacotherapy Provides Rapid Relief but Requires Careful Management.** Stimulants (amphetamines, methylphenidate) are highly effective for short-term reduction of core ADHD symptoms, while SSRIs/SNRIs are the first-line medications for PTSD. [executive_summary[1]][7] [executive_summary[0]][8] However, their benefits are often not sustained long-term, with high discontinuation rates due to side effects, cardiovascular risks, and misuse potential. [modern_medical_and_psychological_treatments.pharmacological_treatments[0]][7] Emerging evidence suggests stimulants can be used safely in comorbid populations and may even improve PTSD symptoms, but this requires slow, careful titration and monitoring. [framework_for_personalized_treatment.treatment_sequencing_and_integration[3]][9]

**Foundational Lifestyle Interventions Are High-ROI and Low-Risk.** Sleep optimization, regular physical exercise, and mindfulness are not merely adjunctive but foundational to recovery. Poor sleep is a core, debilitating feature of both disorders; interventions like CBT for Insomnia (CBT-I) are highly effective and safe. Regular aerobic exercise has demonstrated significant benefits for both ADHD (improving executive function) and PTSD (reducing symptoms) with virtually no risk. [lifestyle_and_behavioral_interventions.exercise_interventions[3]][10] These interventions are highly accessible and should be implemented as a non-negotiable baseline for any treatment plan.

**Emerging Technologies and Therapies Show Promise but Carry Caveats.** Neuromodulation techniques like rTMS show moderate efficacy for treatment-resistant cases of both PTSD and ADHD, but effects may not be durable and costs are prohibitive. [neuromodulation_and_brain_stimulation_therapies.evidence_for_ptsd[0]][11] Psychedelic-assisted therapies, particularly MDMA for PTSD, showed high efficacy in trials but were rejected by the FDA in 2024 due to significant concerns about trial integrity and safety, halting their clinical availability for the foreseeable future. [psychedelic_and_dissociative_assisted_therapies.legal_and_regulatory_status_2025[0]][12] In contrast, digital therapeutics like EndeavorRx (ADHD) and NightWare (PTSD nightmares), along with HRV biofeedback tools, represent a new, FDA-authorized frontier in accessible, scalable care that can be integrated into a broader treatment plan. [digital_therapeutics_and_technology_tools[0]][13] [digital_therapeutics_and_technology_tools[12]][14]

## Multi-Criteria Comparative Effectiveness Table for Adult ADHD and Trauma Interventions

**Rationale & Limitations:** This table synthesizes evidence across multiple domains to provide a comparative overview. Scores are qualitative ratings (High, Moderate, Low, Very Low/Unknown) based on the weight of evidence from meta-analyses, RCTs, and clinical guidelines. A critical limitation is the **scarcity of research specifically on the comorbid adult ADHD and PTSD population**. Therefore, many ratings are extrapolated from studies on each condition individually. The 'Overall Effectiveness' score is a qualitative synthesis, not a quantitative calculation, and should be interpreted with caution. User preferences (e.g., prioritizing safety over efficacy) will alter the personal relevance of each intervention.

| Intervention Category | Specific Intervention | Primary Target | Magnitude of Benefit (Efficacy) | Durability of Effect | Safety & Tolerability | Cost & Access | Required Effort | Evidence Certainty | Overall Effectiveness & Use-Case |
|---|---|---|---|---|---|---|---|---|---|
| **Pharmacotherapy** | **Stimulants (Amphetamines, Methylphenidate)** | ADHD | **High** (SMD -0.5 to -0.8 for core symptoms) | **Low/Unknown** (Poor long-term data; high discontinuation rates) | **Low-Moderate** (High dropout due to side effects; cardiovascular risks; misuse potential) | **Moderate** (Generics available but brand names are expensive; access requires diagnosis) | **Low** (Daily pill) | **High** (for short-term) | **High (Short-Term):** First-line for rapid reduction of core ADHD symptoms. Requires careful monitoring. Potential to worsen anxiety in some PTSD patients. |
| | **Non-Stimulants (Atomoxetine, Guanfacine)** | ADHD | **Moderate** (SMD -0.45 for core symptoms) | **Low/Unknown** (Limited long-term data) | **Moderate** (Better tolerated than stimulants by some, but still has side effects) | **Moderate** (Generic atomoxetine is affordable) | **Low** (Daily pill) | **High** | **Moderate:** Second-line for ADHD, or for those with contraindications/intolerance to stimulants or high misuse risk. |
| | **SSRIs/SNRIs (Sertraline, Paroxetine, Venlafaxine)** | PTSD | **Moderate** (Response rate ~39-60%) | **Moderate** (Benefits can be sustained with continued use) | **Moderate** (Side effects like sexual dysfunction, withdrawal syndrome) | **High** (Generics widely available and affordable) | **Low** (Daily pill) | **High** | **Moderate:** First-line pharmacotherapy for PTSD, but less effective than trauma-focused psychotherapy. |
| **Psychotherapy** | **Trauma-Focused (EMDR, CPT, PE, NET)** | PTSD | **High** (Large effect sizes, SMD > 0.8; high remission rates) | **High** (Benefits are sustained long-term post-treatment) | **High** (Generally safe; low dropout rates; symptom spikes are rare) | **Low** (High cost per session; long waitlists; provider scarcity) | **High** (Weekly sessions, homework, emotional processing) | **High** | **Very High:** Gold-standard, first-line treatment for PTSD with durable, transformative effects. The most effective approach for the trauma component. |
| | **CBT for ADHD** | ADHD, Comorbid Anxiety/Depression | **High** (Large effect sizes, g = 1.0 pre-post) | **High** (Skills-based, benefits are durable) | **High** (Very safe, low risk of adverse events) | **Low** (High cost per session; long waitlists) | **High** (Weekly sessions, skills practice) | **High** | **Very High:** Most effective non-pharmacological treatment for adult ADHD. Also effective for common comorbid anxiety and depression. |
| | **DBT-informed Therapy** | ADHD (Emotion Regulation), PTSD | **Moderate-High** (SMD -0.51 for ADHD symptoms; improves QoL) | **Moderate** (Benefits persist at 6-month follow-up) | **High** (Very safe) | **Low** (High cost; often delivered in groups) | **High** (Skills training, group sessions) | **Moderate** | **High:** Excellent choice for individuals where emotional dysregulation is a primary feature of both ADHD and trauma. |
| **Neuromodulation** | **rTMS (Repetitive Transcranial Magnetic Stimulation)** | PTSD, ADHD (Inattention) | **Moderate** (SMD -0.5 to -0.9 for acute PTSD; SMD -0.76 for ADHD inattention) | **Low** (PTSD effects often not sustained at follow-up) | **High** (Generally safe; rare risk of seizure) | **Very Low** (Very expensive; limited insurance coverage; requires daily clinic visits) | **Moderate-High** (Requires daily sessions for several weeks) | **Moderate** | **Moderate:** A promising option for treatment-resistant cases of PTSD or ADHD, but access and durability are major limitations. |
| | **EEG Neurofeedback** | ADHD | **Low/Inconsistent** (Blinded studies show minimal effect; placebo effect is high) | **Unknown** (Conflicting data) | **High** (Non-invasive and safe) | **Very Low** (Very expensive, not covered by insurance, time-consuming) | **High** (Requires many sessions) | **Very Low** | **Low:** Not recommended as a primary treatment due to inconsistent evidence and high cost. |
| **Somatic & Lifestyle** | **Exercise (Aerobic, HIIT, Yoga)** | Both | **Moderate** (Improves ADHD executive function & PTSD symptoms) | **High** (Benefits persist with continued practice) | **Very High** (Safe for most people) | **High** (Can be free or low-cost) | **Moderate** (Requires regular time commitment) | **Moderate** | **High:** A foundational, highly accessible intervention with broad benefits for mental and physical health. Excellent adjunctive treatment. |
| | **Mindfulness & Breathwork** | Both | **Moderate** (Reduces symptoms of both ADHD and PTSD) | **High** (Skills are durable with practice) | **Moderate-High** (Generally safe, but can cause adverse effects like dissociation in vulnerable individuals) | **High** (Many free/low-cost apps and resources) | **Moderate** (Requires daily practice) | **Moderate** | **High:** Highly effective for improving emotion regulation, attention, and reducing hyperarousal. Trauma-sensitive approaches are recommended. |
| | **Sleep Optimization (CBT-I, Light Therapy)** | Both | **High** (Significantly improves sleep and reduces PTSD/ADHD symptoms) | **High** (Skills are durable) | **Very High** (Very safe) | **Moderate** (CBT-I can be costly, but digital versions are emerging) | **Moderate-High** (Requires behavioral changes and consistency) | **High** | **Very High:** Critical intervention, as sleep disruption is a core, debilitating feature of both conditions. |
| **Psychedelic-Assisted** | **MDMA-Assisted Therapy** | PTSD | **High (in trials)** | **Unknown (in real world)** | **Low** (FDA rejected due to safety, data integrity, and abuse concerns) | **Very Low** (Not legally available; high projected cost) | **High** (Intensive multi-session protocol) | **Low (Regulatory)** | **Not Recommended (Currently):** Not an approved treatment. Future depends on addressing significant safety and trial conduct issues. |
| | **Ketamine/Esketamine** | PTSD, Depression | **High (Rapid Onset)** | **Low** (Effects are often transient, requiring repeated infusions) | **Moderate** (Requires medical monitoring for blood pressure, dissociation; abuse potential) | **Very Low** (Very expensive; limited insurance coverage) | **Moderate** (Requires clinic visits and monitoring) | **Moderate** | **Moderate:** Best used for rapid stabilization in severe, treatment-resistant cases of depression or PTSD, but not a long-term solution. |
| **Traditional & Supplements** | **TCM (Acupuncture) & Ayurveda (Herbs)** | Both | **Low-Moderate** (Some positive studies but often low quality) | **Unknown** | **Low-Moderate** (Risk of herb-drug interactions and contamination) | **Moderate** (Cost varies; not typically covered by insurance) | **Moderate** (Requires regular sessions/dosing) | **Very Low** | **Low:** May offer adjunctive benefits for some, but not a substitute for evidence-based care due to weak evidence and safety concerns. |
| | **Nutraceuticals (Omega-3, Saffron, etc.)** | ADHD | **Low** (Omega-3 evidence is inconsistent; others are emerging) | **Unknown** | **Moderate** (Generally safe, but interactions are possible) | **High** (Widely available OTC, but can be costly) | **Low** (Daily pill) | **Very Low** | **Low:** May provide minor adjunctive support (e.g., long-term Omega-3), but not a primary treatment. Quality control is a concern. |

This table synthesizes data from multiple sources, including but not limited to [comparative_effectiveness_table[0]][7] and [comparative_effectiveness_table[1]][15].

## Modern Medical and Psychological Treatments

### Pharmacological Treatments: The First Line for Symptom Management

For adult ADHD, pharmacological intervention is a primary strategy for managing core symptoms. [modern_medical_and_psychological_treatments.pharmacological_treatments[0]][7]
* **Stimulants (First-Line for ADHD):** Medications like amphetamines (e.g., lisdexamfetamine/Vyvanse) and methylphenidate are considered first-line treatments by major guidelines from NICE and CADDRA. [modern_medical_and_psychological_treatments.pharmacological_treatments[2]][16] A 2025 network meta-analysis confirmed stimulants were the only intervention with clear short-term efficacy for core symptoms (SMD = -0.43) and also moderately improve Quality of Life (QoL), with amphetamines showing a Hedge's g of 0.51. [modern_medical_and_psychological_treatments.pharmacological_treatments[0]][7] [modern_medical_and_psychological_treatments.pharmacological_treatments[1]][15]
* **Non-Stimulants (Second-Line for ADHD):** Atomoxetine, bupropion, and guanfacine are second-line options, often used when stimulants are not tolerated or pose a misuse risk. [modern_medical_and_psychological_treatments.pharmacological_treatments[0]][7] Atomoxetine shows similar efficacy to stimulants for core symptoms (SMD = -0.36) but has lower patient acceptability. [modern_medical_and_psychological_treatments.pharmacological_treatments[0]][7]
* **SSRIs/SNRIs (First-Line for PTSD):** For PTSD, the 2023 VA/DoD guidelines strongly recommend SSRIs (sertraline, paroxetine) and the SNRI venlafaxine as first-line monotherapy. [modern_medical_and_psychological_treatments.pharmacological_treatments[3]][8] Response rates for sertraline are around **53%**, and venlafaxine has shown remission rates of **50.9%**. 
* **Other PTSD Medications:** The guidelines strongly recommend against benzodiazepines and cannabis. Evidence for prazosin for nightmares is mixed; while a large VA study found it ineffective, a 2025 meta-analysis found it significantly improved nightmares (SMD = -0.641). 
* **Comorbid Treatment:** For comorbid ADHD and PTSD, treatment must be individualized. Emerging evidence suggests that treating ADHD with stimulants may concurrently improve PTSD symptoms. A pilot RCT found methylphenidate improved PTSD symptoms in TBI patients without increasing hyperarousal. 

### Psychological Treatments: The Gold Standard for Durable Change

For both conditions, psychotherapy is considered the gold standard for achieving long-term, durable improvements in functioning and well-being.
* **CBT for ADHD:** Cognitive Behavioral Therapy (CBT) is the most effective and well-researched psychotherapy for adult ADHD. A 2025 network meta-analysis found it to be the most effective non-pharmacological intervention, with significant short-term (SMD: -4.43) and long-term (SMD: -3.61) reduction in core symptoms, as well as benefits for comorbid depression and anxiety. 
* **Other ADHD Therapies:** Other promising therapies include Metacognitive Therapy (MCT) for executive functioning and Dialectical Behavior Therapy (DBT)-informed approaches, which are superior to treatment-as-usual for executive dysfunction (effect size 0.64). 
* **Trauma-Focused Psychotherapies for PTSD:** These are the first-line treatment for PTSD. The 2025 APA guidelines give the highest recommendation to Cognitive Processing Therapy (CPT), Prolonged Exposure (PE), and Trauma-Focused CBT (TF-CBT). Network meta-analyses consistently find these, along with Eye Movement Desensitization and Reprocessing (EMDR) and Narrative Exposure Therapy (NET), to be highly effective. 
* **Therapies for Complex Trauma (CPTSD):** For trauma that is chronic or developmental, phase-based approaches are recommended. STAIR (Skills Training in Affective and Interpersonal Regulation) is a leading therapy for CPTSD with large effect sizes (d = 1.34 to 2.29). Internal Family Systems (IFS) and Somatic Experiencing (SE) are promising emerging therapies. 

It is a common but largely unfounded concern that these therapies will worsen symptoms; dropout rates average a manageable **16-21%**, and there is no evidence of widespread symptom exacerbation during treatment. 

## Neuromodulation and Brain Stimulation Therapies

These therapies directly target the brain circuits implicated in ADHD and PTSD, offering a non-pharmacological approach for treatment-resistant cases. The primary technique is Repetitive Transcranial Magnetic Stimulation (rTMS) and its variant, intermittent Theta Burst Stimulation (iTBS). [neuromodulation_and_brain_stimulation_therapies.technique_name[0]][17] [neuromodulation_and_brain_stimulation_therapies.technique_name[1]][18]

### Evidence for ADHD: Promising for Inattention, but Inconsistent Overall

The evidence for rTMS in adult ADHD is mixed but shows potential for specific symptoms. While a 2025 meta-analysis found no significant overall improvements, other analyses have been more positive. 
* A 2024 meta-analysis found that rTMS targeting the right prefrontal cortex (rPFC) was more effective than sham (SMD = -0.49) and specifically improved inattention (SMD = -0.76). 
* A 2023 meta-analysis found rTMS effective for improving sustained attention (SMD = 0.54) and processing speed (SMD = 0.59), though not memory or executive function. [neuromodulation_and_brain_stimulation_therapies.evidence_for_adhd[0]][17]
This suggests that while not a cure-all, targeted rTMS may be beneficial for the inattentive aspects of ADHD.

### Evidence for PTSD: Effective for Acute Symptoms, but Long-Term Effects Unclear

For PTSD, multiple meta-analyses support the acute efficacy of rTMS, though benefits may not be sustained. [neuromodulation_and_brain_stimulation_therapies.evidence_for_ptsd[1]][18]
* An August 2024 network meta-analysis found that high-frequency rTMS (HF-rTMS) (SMD = -0.97), iTBS (SMD = -0.93), and low-frequency rTMS (LF-rTMS) (SMD = -0.76) all significantly reduced PTSD symptoms at the end of treatment. [neuromodulation_and_brain_stimulation_therapies.evidence_for_ptsd[0]][11]
* A key limitation is that these significant effects were not sustained at follow-up. [neuromodulation_and_brain_stimulation_therapies.evidence_for_ptsd[0]][11]
* Another 2024 study found that 20-Hz rTMS applied to the right DLPFC had a greater effect than when applied to the left. 

### Typical Protocol and Safety Status

The primary brain region targeted for both conditions is the dorsolateral prefrontal cortex (DLPFC). [neuromodulation_and_brain_stimulation_therapies.typical_protocol[2]][19]
* **For ADHD:** Protocols stimulating the right DLPFC show the most promise for improving inattention. 
* **For PTSD:** Two main protocols are used: high-frequency stimulation of the left DLPFC (upregulating activity) and low-frequency stimulation of the right DLPFC (downregulating activity). 

rTMS is generally safe and well-tolerated, with a very rare risk of seizure. Despite positive findings, the 2023 VA/DoD Guideline for PTSD states there is insufficient evidence to recommend for or against rTMS, highlighting a conservative stance pending more robust, long-term data. 

## Psychedelic and Dissociative-Assisted Therapies

This category represents a frontier in mental health treatment, with substances like MDMA, ketamine, and psilocybin being investigated for their potential to catalyze therapeutic breakthroughs, particularly for treatment-resistant conditions.

### MDMA (Midomafetamine) for PTSD: High Hopes Meet a Regulatory Wall

MDMA-assisted therapy has been the most prominent psychedelic treatment in development, primarily targeting Post-Traumatic Stress Disorder (PTSD). [psychedelic_and_dissociative_assisted_therapies.substance_name[0]][20] [psychedelic_and_dissociative_assisted_therapies.primary_target_condition[0]][20]
* **Clinical Evidence:** Two pivotal Phase 3 trials, MAPP1 and MAPP2, demonstrated that MDMA-assisted therapy produced statistically significant and clinically meaningful reductions in PTSD symptoms compared to placebo with therapy. [psychedelic_and_dissociative_assisted_therapies.clinical_evidence_summary[0]][20] [psychedelic_and_dissociative_assisted_therapies.clinical_evidence_summary[1]][21]
* **Regulatory Status:** Despite positive efficacy signals, the U.S. FDA rejected the New Drug Application in **August 2024**, following a decisive **10-1 negative vote** from its advisory committee. [psychedelic_and_dissociative_assisted_therapies.legal_and_regulatory_status_2025[0]][12] [psychedelic_and_dissociative_assisted_therapies.legal_and_regulatory_status_2025[2]][22] The FDA has requested at least one additional well-controlled trial. [psychedelic_and_dissociative_assisted_therapies.legal_and_regulatory_status_2025[0]][12]
* **Safety Concerns:** The rejection was driven by serious concerns, including a high rate of "functional unblinding" (over **90%** of participants guessed their treatment), compromising the placebo control; data integrity issues and reports of ethical violations at a trial site; and potential risks of cardiovascular events and worsening mental health symptoms. 

## Lifestyle and Behavioral Interventions

These foundational strategies are highly accessible, low-cost, and offer broad benefits for both mental and physical health, making them a critical first step in any comprehensive treatment plan.

### Exercise Interventions to Regulate the Brain and Body

Regular physical activity has significant therapeutic effects for both ADHD and PTSD.
* **For ADHD:** Exercise enhances inhibitory control and emotional regulation. Typical protocols involve **30-minute** moderate-to-intense sessions held three times weekly. [lifestyle_and_behavioral_interventions.exercise_interventions[0]][23] Even a single 20-minute bout can enhance motivation for cognitive tasks. [lifestyle_and_behavioral_interventions.exercise_interventions[2]][24]
* **For PTSD:** Patients experience reduced symptom severity and anxiety through similar exercise regimens, especially when guided by trained specialists. 

### Sleep Optimization to Restore Foundational Health

Sleep disruption is a core feature of both conditions.
* **CBT-I:** Cognitive Behavioral Therapy for Insomnia (CBT-I), tailored for adult ADHD, can improve sleep quality while also alleviating daytime ADHD symptoms. 
* **Bright Light Therapy (BLT):** This technique is effective in adjusting circadian rhythms, which are often delayed in ADHD and disrupted in PTSD. [lifestyle_and_behavioral_interventions.sleep_optimization_strategies[0]][25] [lifestyle_and_behavioral_interventions.sleep_optimization_strategies[1]][26]

### Nutrition and Dietary Patterns to Support Cognitive Function

Dietary choices can influence symptom severity.
* **Mediterranean Diet:** Emphasizing fruits, vegetables, and omega-3 fatty acids is associated with a lower risk of ADHD and can support cognitive function. [lifestyle_and_behavioral_interventions.nutrition_and_dietary_patterns[0]][27] [lifestyle_and_behavioral_interventions.nutrition_and_dietary_patterns[1]][28]
* **Elimination Diets:** For some individuals, specific elimination diets may help identify and remove foods that trigger or worsen symptoms. 

### Impact of Common Substances on Symptoms

Substances like caffeine, alcohol, and nicotine have complex and often detrimental effects.
* **Caffeine:** Low doses may enhance focus in ADHD, but overconsumption can worsen anxiety and hyperarousal in PTSD. 
* **Alcohol:** Often used as a maladaptive coping mechanism, alcohol can increase symptom severity in both conditions. 
* **Nicotine:** While providing an acute calming effect, its long-term health risks and addictive potential outweigh any perceived benefits. 

## Somatic and Body-Oriented Practices

These practices directly target the autonomic nervous system dysregulation and physical tension that are central to the experience of trauma and ADHD, helping to "shake off" symptoms from the body.

Integrative Yoga and Trauma-Sensitive Yoga, which combine physical postures with breathwork, are effective for facilitating emotional regulation and processing trauma. [somatic_and_body_oriented_practices[0]][29] Techniques like box breathing and other voluntary regulated breathing practices cultivate mindfulness and directly lower hyperarousal by improving vagal tone. [somatic_and_body_oriented_practices[1]][30] [somatic_and_body_oriented_practices[5]][31] Mind-body practices like Tai Chi and Qigong have also shown potential to reduce symptoms and improve functioning for individuals exposed to trauma. [somatic_and_body_oriented_practices[11]][32] [somatic_and_body_oriented_practices[12]][33] Consistent practice, performed daily or several times a week over an extended period, is required to see lasting benefits. 

## Nutraceuticals and Dietary Supplements

While not a replacement for primary treatments, certain supplements may offer adjunctive support. However, quality control and potential for drug interactions are significant concerns.

### Omega-3 Fatty Acids: A Modest but Safe Adjunct

Omega-3 fatty acids are the most studied supplement for these conditions. [nutraceuticals_and_dietary_supplements.supplement_name[0]][34]
* **Evidence for ADHD:** Meta-analyses suggest potential, albeit modest, benefits for attention and emotional regulation. Some studies indicate that long-term supplementation may be beneficial, even if core symptoms are not immediately improved. [nutraceuticals_and_dietary_supplements.evidence_for_adhd[3]][35]
* **Evidence for PTSD:** Evidence suggests a role in reducing inflammatory responses associated with PTSD and may offer protection against developing the disorder after trauma. [nutraceuticals_and_dietary_supplements.evidence_for_ptsd[0]][34]
* **Dosing and Safety:** Supported dosing is typically **750–1500 mg** daily of combined EPA and DHA. Omega-3s are generally well-tolerated but should be monitored if combined with anticoagulants. It is crucial to source products that are third-party certified for purity to avoid contaminants and rancidity. 

## Traditional and Ancient Healing Systems

Systems like Traditional Chinese Medicine (TCM), Ayurveda, and Indigenous healing practices offer holistic approaches that have been used for thousands of years. While the quality of scientific evidence is often low to moderate, these practices can offer culturally relevant and supportive care.

* **Acupuncture (TCM):** For PTSD, evidence is encouraging, with one RCT finding it superior to a waitlist control and similar in effect to CBT. [traditional_and_ancient_healing_systems[1]][36] Another trial found verum acupuncture resulted in a larger reduction in PTSD symptoms than sham acupuncture. [traditional_and_ancient_healing_systems[0]][37] For ADHD, the evidence is weaker, with a 2011 Cochrane Review finding no high-quality trials to support its use. [traditional_and_ancient_healing_systems[2]][38]
* **Herbal Adaptogens (Ayurveda):**
 * **Bacopa monnieri (Brahmi):** A systematic review found it was safe and demonstrated small to medium effect sizes for improving cognition, behavior, and attention in children and adolescents. [traditional_and_ancient_healing_systems[6]][39] However, a recent RCT in children with ADHD found no significant improvement in behavioral outcomes. [traditional_and_ancient_healing_systems[5]][40]
 * **Ashwagandha:** Studies show it can significantly reduce stress and anxiety levels. [traditional_and_ancient_healing_systems[25]][41] [traditional_and_ancient_healing_systems[28]][42]
* **Indigenous Medicine Practices:** These practices, which often involve family, community, and spiritual ceremony, have shown promising results for healing PTSD in Native populations. [traditional_and_ancient_healing_systems[9]][43] However, research is limited and must be culturally grounded. [traditional_and_ancient_healing_systems[8]][44]

**Safety is a primary concern.** Ayurvedic herbal products have been associated with heavy metal (lead, mercury, arsenic) contamination. [traditional_and_ancient_healing_systems[10]][45] [traditional_and_ancient_healing_systems[11]][46] Herbal remedies can also have significant drug interactions. [traditional_and_ancient_healing_systems[16]][47]

## Digital Therapeutics and Technology Tools

Technology-assisted treatments offer scalable, accessible, and objective options for managing ADHD and PTSD, best used as adjunctive tools within a comprehensive, clinician-led care plan.

### FDA-Authorized Digital Therapeutics (DTx)

* **EndeavorRx (for ADHD):** An FDA-authorized prescription video game for children aged 8-12 designed to improve attention. [digital_therapeutics_and_technology_tools[0]][13] Its pivotal trial showed significant improvement in objective attention measures. [digital_therapeutics_and_technology_tools[0]][13] It is intended as part of a broader treatment program. 
* **NightWare (for PTSD):** An FDA-authorized prescription device using an Apple Watch to detect and interrupt nightmares via gentle vibrations. [digital_therapeutics_and_technology_tools[12]][14] A sham-controlled trial showed trends toward improvement in PTSD-related sleep issues. [digital_therapeutics_and_technology_tools[11]][48]

### Digital Therapy Platforms and Cognitive Training

* **Internet-Delivered CBT (iCBT) for PTSD:** Meta-analyses confirm iCBT is effective, especially when guided by a therapist (pooled effect size g=0.54). However, high dropout rates (over **40%**) can be a challenge. 
* **Virtual Reality Exposure Therapy (VRET):** A promising treatment for PTSD with efficacy comparable to other active psychotherapies. [digital_therapeutics_and_technology_tools[16]][49]
* **Computerized Cognitive Training (CCT) for ADHD:** Evidence for CCT and working memory training (e.g., Cogmed) is weak and inconsistent, with meta-analyses finding small to near-zero effects on core symptoms and far-transfer measures. 

### Wearables and Biofeedback

* **Heart Rate Variability (HRV) Biofeedback:** A highly promising intervention for PTSD. Low HRV is a biomarker for PTSD, and HRVB aims to increase it through slow-paced breathing. A 2024 meta-analysis on military PTSD found HRVB led to a substantial reduction in symptoms (effect sizes from -1.614 to -0.414). 

## Community, Environmental, and Skills-Based Support

A comprehensive approach must extend beyond clinical interventions to include skills, environmental modifications, and community support to improve daily functioning.

* **ADHD Coaching & Organizational Systems:** ADHD coaching is an effective intervention targeting core challenges like planning and time management, leading to improved executive functioning. [community_environmental_and_skills_based_support[0]][50] [community_environmental_and_skills_based_support[100]][51] Techniques like the Pomodoro Technique help manage 'time blindness', while external memory aids (whiteboards, timers) are crucial for compensating for working memory deficits. [community_environmental_and_skills_based_support[2]][52] [community_environmental_and_skills_based_support[4]][53]
* **Environmental Engineering & Sensory Modulation:** Modifying one's surroundings to control distractions and sensory input is a first-line strategy. [community_environmental_and_skills_based_support[92]][54] This includes creating quiet workspaces and using tools like noise-canceling headphones. [community_environmental_and_skills_based_support[110]][55] Occupational therapists can help create a personalized 'sensory diet' using weighted blankets or movement breaks to manage sensory overload common in both ADHD and PTSD. [community_environmental_and_skills_based_support[109]][56]
* **Social and Community Support:** Peer-led groups foster connection through shared experience, reducing anxiety. [community_environmental_and_skills_based_support[76]][57] Faith and spirituality-based practices can offer structured social networks and reduce post-traumatic stress. [community_environmental_and_skills_based_support[91]][58]
* **Nature-Based Interventions:** Exposure to green spaces or 'forest bathing' (Shinrin-Yoku) is strongly supported by evidence for reducing ADHD symptom severity and has a moderate effect on PTSD symptoms. [community_environmental_and_skills_based_support[84]][59] [community_environmental_and_skills_based_support[92]][54]
* **Workplace and School Accommodations:** In the U.S., the Americans with Disabilities Act (ADA) mandates reasonable accommodations like flexible schedules and quiet workspaces to ensure equal opportunity. [community_environmental_and_skills_based_support[98]][60]

## A Framework for Personalized Treatment

Effective management of comorbid ADHD and trauma is not a one-size-fits-all process. It requires a personalized framework that sequences interventions, considers individual predictors of response, and uses data to guide decisions.

### Treatment Sequencing and Integration: A Step-Care Algorithm

Clinical guidelines advocate for a concurrent treatment model, addressing both ADHD and PTSD simultaneously whenever possible. 
1. **Prioritize Safety:** Active suicidality, psychosis, or severe substance use must be stabilized first. 
2. **Target the Most Impairing Condition:** Generally, the condition causing the most functional impairment should be addressed first. In many cases, treating PTSD first is recommended, as depression and other symptoms often improve with successful trauma treatment. 
3. **Consider an ADHD-First Approach (with caution):** In some cases, effective ADHD treatment can improve mood and the capacity to engage in trauma therapy. Stimulants can be a viable option but require slow titration and careful monitoring for any increase in hyperarousal. 
4. **Combine Modalities:** Combining psychotherapy and pharmacotherapy is a common and effective strategy, particularly for ADHD. 

### Patient Factors Predicting Response: Identifying What Works for Whom

Personalizing treatment requires understanding which factors predict success.
* **For ADHD:** Baseline symptom severity, comorbid emotional dysregulation, and parental psychopathology can all moderate treatment response. Biological predictors like genetic markers (e.g., DAT1 gene) and EEG patterns (e.g., theta/beta ratio) are emerging but still under investigation. 
* **For PTSD:** Higher pre-treatment symptom severity and dissociation predict less favorable outcomes. Trauma type (combat vs. assault) and age also matter. Genetic markers like FKBP5 are well-documented risk factors. Advanced machine learning models are being developed to create a Personalized Advantage Index (PAI) to predict the optimal therapy for an individual. 

### Measurement-Based Care Strategy: Using Data to Drive Decisions

A robust measurement-based care strategy is essential for tracking progress and personalizing interventions over time. This involves using a combination of validated clinical scales and objective digital metrics.

| Measurement Category | Recommended Tools | Purpose |
|---|---|---|
| **ADHD Symptoms** | Adult ADHD Self-Report Scale (ASRS-v1.1), ADHD Rating Scale-5 (ADHD-RS-5) | Track core symptoms of inattention and hyperactivity/impulsivity. [framework_for_personalized_treatment.measurement_based_care_strategy[8]][61] [framework_for_personalized_treatment.measurement_based_care_strategy[9]][62] |
| **Trauma Symptoms** | PTSD Checklist for DSM-5 (PCL-5) | Monitor severity of PTSD symptom clusters. [framework_for_personalized_treatment.measurement_based_care_strategy[10]][63] |
| **Comorbidities** | Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder-7 (GAD-7) | Screen for and track depression and anxiety. [framework_for_personalized_treatment.measurement_based_care_strategy[11]][64] |
| **Overall Well-being** | WHO Quality of Life-BREF (WHOQOL-BREF) | Assess overall quality of life across multiple domains. |
| **Objective Metrics** | Wearables (Oura Ring), Actigraphy, HRV monitors, Digital CPT | Track sleep, autonomic regulation, activity levels, and cognitive performance. |

To scientifically determine the best intervention for an individual, **N-of-1 trial designs** are highly effective. These single-subject trials use a framework like **Bayesian inference** to compare different treatments within one person, allowing for truly data-driven, personalized decisions. [framework_for_personalized_treatment.measurement_based_care_strategy[1]][65] [framework_for_personalized_treatment.measurement_based_care_strategy[2]][66]

## Comprehensive Safety and Harm Reduction Guide

A core principle of treatment is "first, do no harm." This requires a thorough understanding of the risks and contraindications of each intervention.

* **ADHD Medications:** Stimulants carry cardiovascular risks and require monitoring of blood pressure and heart rate. [comprehensive_safety_and_harm_reduction_guide[3]][16] They also have a significant risk of misuse and diversion. [comprehensive_safety_and_harm_reduction_guide[3]][16] Non-stimulants like atomoxetine carry rare risks of severe liver injury. [comprehensive_safety_and_harm_reduction_guide[20]][67]
* **PTSD Medications:** SSRIs/SNRIs have a Black Box warning for increased suicidality in young adults and can cause discontinuation syndrome. 
* **Psychotherapy:** While generally safe, there is a small risk of symptom exacerbation if not conducted with care by a trained professional. 
* **Neuromodulation:** rTMS has a rare but serious risk of seizure. 
* **Supplements & Herbal Remedies:** These are not regulated by the FDA and pose risks of contamination and drug interactions. St. John's Wort, Ginkgo biloba, and Saffron can all have dangerous interactions with prescription medications. 
* **Psychedelic & Dissociative Therapies:** These carry unique and significant risks. Esketamine (Spravato) requires a strict REMS program due to risks of sedation and blood pressure spikes. [comprehensive_safety_and_harm_reduction_guide[19]][68] Ibogaine carries a risk of fatal cardiac arrhythmia. 

Harm reduction relies on comprehensive screening, informed consent, and structured monitoring protocols to ensure patient safety across all treatments. 

## Cost, Access, and Policy Considerations

The availability of effective treatments is meaningless if they are not accessible. Cost, provider availability, and policy create significant barriers to care.

### Costs and Insurance Coverage Create a Two-Tiered System

The cost of care varies dramatically, creating significant disparities.
* **Medications:** In the U.S., brand-name Adderall can cost over **$800/month**, while generic atomoxetine can be as low as **$15/month**. [cost_access_and_policy_considerations.costs_and_insurance_coverage[0]][69]
* **Psychotherapy:** Sessions in the U.S. typically cost **$100-$250** out-of-pocket. [cost_access_and_policy_considerations.costs_and_insurance_coverage[1]][70]
* **International Variations:** In the UK, private ADHD assessments can cost **~£695**. [cost_access_and_policy_considerations.costs_and_insurance_coverage[3]][71] In Australia, PBS restrictions mean adults diagnosed later in life face higher medication costs. [cost_access_and_policy_considerations.equity_and_access_barriers[0]][72]
* **Digital Therapeutics:** EndeavorRx costs **$99** for a 30-day prescription in the US, while in Germany, approved digital health apps (DiGAs) are reimbursed by statutory health insurance. 

### Provider Shortages and Long Waitlists Delay Critical Care

Access to specialists is severely constrained globally.
* **United States:** Faces a projected deficit of over **17,000** psychiatrists by 2050. 
* **United Kingdom:** Adults can wait an average of over **1.5 years** for an NHS ADHD assessment. [cost_access_and_policy_considerations.provider_availability_and_waitlists[1]][6]
* **Canada & Australia:** Report long wait times for community mental health counseling (nearly five months for 1 in 10 people in Canada) and specialists (median wait of 50 days in Australia). 

### The Evolving Legal and Regulatory Landscape for Novel Treatments

The legal status of emerging therapies is a critical and dynamic factor.
* **Psychedelics:** The **August 2024** FDA rejection of MDMA for PTSD has created a major hurdle for federal approval, though states like Oregon and Colorado have legalized psilocybin for therapeutic use. 
* **Stellate Ganglion Block (SGB):** The VA/DOD considers SGB for PTSD to be a non-established treatment with inconclusive evidence, though legislation has been introduced in Congress to mandate its availability for veterans. [cost_access_and_policy_considerations.legal_and_regulatory_landscape[3]][73] [cost_access_and_policy_considerations.legal_and_regulatory_landscape[2]][74]

### Equity and Access Barriers Disadvantage Vulnerable Populations

Significant equity barriers prevent many from receiving care. Socioeconomic disparities, systemic psychiatrist shortages impacting rural areas, and long public waitlists create a system where those who can afford private care receive it faster, while others are left behind.

## References

1. *Overview of Psychotherapy for PTSD*. https://www.ptsd.va.gov/professional/treat/txessentials/overview_therapy.asp
2. *Psychological therapies for post-traumatic stress disorder ...*. https://pubmed.ncbi.nlm.nih.gov/32284821/
3. *APA Guidelines on Treating PTSD and Trauma in Adults (2025)*. https://www.apa.org/monitor/2025/07-08/guidelines-treating-ptsd-trauma
4. *Short-term and long-term effect of non-pharmacotherapy for adults with ADHD: a systematic review and network meta-analysis*. https://pmc.ncbi.nlm.nih.gov/articles/PMC11825462/
5. *Short-term and long-term effect of non-pharmacotherapy ...*. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2025.1516878/full
6. *Average 618-day wait for adult ADHD assessment - BBC*. https://www.bbc.com/news/articles/c5ypk245yp4o
7. *Lancet Psychiatry Ostinelli et al., 2025 (ADHD in adults: pharmacological treatments and network meta-analysis)*. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(24)00360-2/fulltext
8. *PTSD VA/DoD Clinical Practice Guideline (2023)*. https://www.ptsd.va.gov/professional/treat/txessentials/clinician_guide_meds.asp
9. *Comorbidity moderates response to methylphenidate in ... - PubMed*. https://pubmed.ncbi.nlm.nih.gov/17979578/
10. *ADHD, Physical Activity, and Neurobiological Mechanisms*. https://pmc.ncbi.nlm.nih.gov/articles/PMC11941119/
11. *Neuromodulation treatments for post-traumatic stress disorder: a systematic review and network meta-analysis covering efficacy, acceptability, and follow-up effects*. https://www.sciencedirect.com/science/article/abs/pii/S0887618524000884
12. *FDA Issues CRL to Lykos for MDMA-Assisted Therapy*. https://www.psychiatrictimes.com/view/fda-issues-crl-to-lykos-for-mdma-assisted-therapy
13. *STARS-ADHD Trial of AKL-T01 (EndeavorRx)*. https://www.thelancet.com/journals/landig/article/PIIS2589-7500(20)30017-0/fulltext
14. *Veterans find relief from nightmares with NightWare and ...*. https://www.apple.com/newsroom/2022/11/veterans-find-relief-from-nightmares-with-nightware-and-apple-watch/
15. *Pharmacological Treatments for ADHD QoL and Efficacy – Meta-analytic Synthesis (Sciencedirect)*. https://www.sciencedirect.com/science/article/pii/S0890856724003046
16. *NICE NG87: Attention Deficit Hyperactivity Disorder in Adults - Recommendations*. https://www.nice.org.uk/guidance/ng87/chapter/recommendations
17. *PMCID: PMC10580630 – Therapeutic efficacy of rTMS for ADHD (Chen et al., 2023)*. https://pmc.ncbi.nlm.nih.gov/articles/PMC10580630/
18. *Repetitive transcranial magnetic stimulation for PTSD (PMCID: PMC11475085)*. https://pmc.ncbi.nlm.nih.gov/articles/PMC11475085/
19. *Low-frequency repetitive transcranial magnetic stimulation ...*. https://pubmed.ncbi.nlm.nih.gov/39411406/
20. *MDMA-assisted therapy for moderate to severe PTSD: a randomized ...*. https://pmc.ncbi.nlm.nih.gov/articles/PMC10579091/
21. *A Multi-Site Phase 3 Study of MDMA-Assisted Therapy ...*. https://maps.org/mdma/ptsd/mapp1/
22. *FDA Psychopharmacologic Advisory Committee Votes ...*. https://www.hcplive.com/view/live-updates-fda-psychopharmacologic-advisory-committee-meeting-mdma-ptsd
23. *Feasibility and tolerability of moderate intensity regular ...*. https://www.frontiersin.org/journals/sports-and-active-living/articles/10.3389/fspor.2023.1133256/full
24. *Association of exercise and ADHD symptoms: Analysis within ...*. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0314508
25. *Treatment of attention deficit hyperactivity disorder ...*. https://www.dovepress.com/article/download/11876
26. *Correcting delayed circadian phase with bright light ...*. https://www.sciencedirect.com/science/article/abs/pii/S0022395616307579
27. *Dietary Alignment with the Mediterranean Diet is Associated with a Lower Risk of Attention Deficit Hyperactivity Disorder in University Students: A Cross-Sectional Study*. https://www.tandfonline.com/doi/full/10.1080/27697061.2025.2480140?src=exp-la
28. *ADHD Nutrition and Diet Review (PMC 2023)*. https://pmc.ncbi.nlm.nih.gov/articles/PMC10444659/
29. *The integration of yoga breathing techniques in cognitive ...*. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1101046/full
30. *Health Technology Assessment: Breathing Practices for Stress and Anxiety*. https://pmc.ncbi.nlm.nih.gov/articles/PMC10741869/
31. *Breathwork interventions for anxiety disorders and related mechanisms (PMCID/ Nature/ PMC review synthesis)*. https://pmc.ncbi.nlm.nih.gov/articles/PMC9954474/
32. *Tai Chi and Qigong for trauma exposed populations: A systematic ...*. https://www.sciencedirect.com/science/article/abs/pii/S1755296622000114
33. *Tai Chi and Qigong for trauma exposed populations: A systematic ...*. https://pubmed.ncbi.nlm.nih.gov/37885833/
34. *Omega-3 polyunsaturated fatty acids in clinical trials for ADHD, PTSD, anxiety, and related conditions*. https://pmc.ncbi.nlm.nih.gov/articles/PMC6324500/
35. *Omega-3 Polyunsaturated Fatty Acids for Core Symptoms ...*. https://pubmed.ncbi.nlm.nih.gov/37656283/
36. *Acupuncture for Posttraumatic Stress Disorder: A Systematic Review of Randomized Controlled Trials and Prospective Clinical Trials*. https://pmc.ncbi.nlm.nih.gov/articles/PMC3580897/
37. *Acupuncture for Combat-Related Posttraumatic Stress ...*. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2814938
38. *Acupuncture for ADHD in children and adolescents (Li 2011 Cochrane Review)*. https://pmc.ncbi.nlm.nih.gov/articles/PMC12147681/
39. *Complementary Therapies in Medicine (Kean et al., 2016)*. https://www.sciencedirect.com/science/article/abs/pii/S0965229916301388
40. *Bacopa monnieri (CDRI 08) randomized trial in children with ADHD (Kean et al., Phytother Res. 2022)*. https://pubmed.ncbi.nlm.nih.gov/35041248/
41. *Ashwagandha: Is it helpful for stress, anxiety, or sleep?*. https://ods.od.nih.gov/factsheets/Ashwagandha-HealthProfessional/
42. *Effects of Withania somnifera (Ashwagandha) on Stress ...*. https://pmc.ncbi.nlm.nih.gov/articles/PMC8762185/
43. *Indigenous Indigenous healing and TIM in PTSD/Trauma (Native healing perspectives)*. https://pmc.ncbi.nlm.nih.gov/articles/PMC3327107/
44. *Am J Community Psychol (Systematic review of trauma interventions in Native communities)*. https://pmc.ncbi.nlm.nih.gov/articles/PMC7243818/
45. *Lead Poisoning Associated with Ayurvedic Medications*. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5326a3.htm
46. *and Indian-Manufactured Ayurvedic Medicines Sold via the ...*. https://jamanetwork.com/journals/jama/fullarticle/182460
47. *Adverse Event Reports Involving Herbal Remedies and ADHD Medications (Mazhar 2020)*. https://pubmed.ncbi.nlm.nih.gov/31670573/
48. *[PDF] A randomized sham-controlled clinical trial of a novel wearable ...*. https://nightware.com/wp-content/uploads/2024/03/NightWare-RCT.pdf
49. *Virtual reality exposure therapy for posttraumatic stress disorder ...*. https://pmc.ncbi.nlm.nih.gov/articles/PMC6713125/
50. *Evidence-Based Coaching for Adults with ADHD - CHADD*. https://chadd.org/attention-article/evidence-based-coaching-for-adults-with-adhd/
51. *Efficacy and acceptability of music therapy for post-traumatic stress ...*. https://pmc.ncbi.nlm.nih.gov/articles/PMC11036901/
52. *Boosting Productivity: Pomodoro Technique for ADHD ...*. https://adhdandautismclinic.co.uk/unleashing-productivity-the-pomodoro-technique-for-adhd-management/
53. *5 Visual Aids That Work Better Than Phone Reminders*. https://www.millennialtherapy.com/anxiety-therapy-blog/visual-memory-aids-adhd
54. *The effectiveness of nature-based interventions in combating PTSD: A meta-analysis and systematic review*. https://www.sciencedirect.com/science/article/abs/pii/S0272494425001100
55. *Clinical Practice Guidelines for PTSD*. https://www.ptsd.va.gov/publications/rq_docs/V35N1.pdf
56. *Efficacy and acceptability of music therapy for post-traumatic stress ...*. https://pubmed.ncbi.nlm.nih.gov/38647566/
57. *Support, Mutual Aid and Recovery from Dual Diagnosis*. https://pmc.ncbi.nlm.nih.gov/articles/PMC1868661/
58. *Religious and spiritual interventions in mental health care: a systematic review and meta-analysis of randomized controlled clinical trials*. https://pmc.ncbi.nlm.nih.gov/articles/PMC4595860/
59. *Greenspace exposure and children behavior: A systematic review*. https://www.sciencedirect.com/science/article/pii/S0048969722007008
60. *Medical empirical research on forest bathing (Shinrin-yoku)*. https://pmc.ncbi.nlm.nih.gov/articles/PMC6886167/
61. *Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 ...*. https://pmc.ncbi.nlm.nih.gov/articles/PMC8066343/
62. *Adult ADHD Self-Report Scale (ASRS)*. https://novopsych.com/assessments/diagnosis/adult-adhd-self-report-scale-asrs/
63. *PCL-5: Scoring and interpretation*. https://comorbidityguidelines.org.au/appendix-s-ptsd-checklist-for-dsm5-pcl5/pcl5-scoring-and-interpretation
64. *The Patient Health Questionnaire Anxiety and Depression ...*. https://pmc.ncbi.nlm.nih.gov/articles/PMC4927366/
65. *Bayesian Models for N-of-1 Trials - PubMed*. https://pubmed.ncbi.nlm.nih.gov/38283071/
66. *The MIT Press/HDSR article on N-of-1 trials and Bayesian inference*. https://hdsr.mitpress.mit.edu/pub/b6efwlql
67. *Lilly Announces Important Liver Safety Update to Strattera ...*. https://investor.lilly.com/news-releases/news-release-details/lilly-announces-important-liver-safety-update-stratterar-label
68. *[PDF] SPRAVATO® (esketamine) nasal spray, CIII - accessdata.fda.gov*. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
69. *ADHD Medication Costs 2025 - SingleCare article*. https://www.singlecare.com/blog/adhd-medication-cost/
70. *Psychology Today: Cost and Insurance Coverage*. https://www.psychologytoday.com/us/basics/therapy/cost-and-insurance-coverage
71. *Our Pricing*. https://www.careadhd.co.uk/pricing
72. *Adults diagnosed with ADHD later in life facing 'unfair' medication ...*. https://www.abc.net.au/news/2021-08-12/adults-with-adhd-facing-unfair-medication-prices/100368890
73. *Stellate Ganglion Block Treatment For PTSD At VA*. https://www.va.gov/HEALTHPARTNERSHIPS/resources/SGBforPTSD_508.pdf
74. *H.R.3023 - 118th Congress (2023-2024): TREAT PTSD Act*. https://www.congress.gov/bill/118th-congress/house-bill/3023/all-info